DGAP-Adhoc: Genmab Enters Broad Collaboration with Janssen Biotech, Inc. for DuoBody Platform

DGAPGenmab A/S12.07.2012 21:09Dissemination of a Adhoc News, transmitted by DGAP - a company ofEquityStory AG.The issuer is solely responsible for the content of this announcement.---------------------------------------------------------------------------Company Announcement -- Genmab enters DuoBody(tm) technology collaboration -- $3.5 million upfront payment to GenmabCopenhagen, Denmark; July 12, 2012 - Genmab A/S (OMX: GEN) announced today ithas entered into a collaboration with Janssen Biotech, Inc. and its affiliates('Janssen') to create and develop bispecific antibodies using its DuoBodytechnology platform. Genmab will create panels of bispecific antibodies tomultiple disease target combinations identified by Janssen, who will in turnfully fund research at Genmab.Under the terms of the agreement, Genmab and Janssen will collaborate on theresearch of up to 10 DuoBody programs and Genmab will receive an upfrontpayment of $3.5 million (DKK 21 million) from Janssen and all research byGenmab will be fully funded by Janssen. In addition, Genmab will potentially beentitled to milestone and license payments of up to approximately $175 million(DKK 1,062 million) for each product as well as royalties on any commercializedproducts.'Since the introduction of our DuoBody platform in 2010, we have believed inits potential to become the preferred technology for next generation bispecificantibody therapeutics. Today's announcement is another indicator that thepharmaceutical industry recognizes our leadership in the therapeutic antibodyfield,' said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. 'Wevery much look forward to working with Janssen in creating trend-settingbispecific antibody treatments.'This agreement is not expected to have a material impact on Genmab's 2012financial guidance.About the DuoBody PlatformThe DuoBody platform is an innovative platform for the discovery anddevelopment of bispecific antibodies that may improve antibody therapy ofcancer, autoimmune, infectious and central nervous system disease. Bispecificantibodies bind to two different epitopes either on the same, or on differenttargets (also known as dual-targeting) which may improve the antibodies'specificity and efficacy in inactivating the disease targets. DuoBody moleculesare unique in combining the benefits of bispecificity with the strengths ofconventional antibodies which allows DuoBody molecules to be administered anddosed as other antibody therapeutics. Genmab's DuoBody platform generatesbispecific antibodies via a fast and broadly applicable process which is easilyperformed at standard bench, as well as commercial, manufacturing scale.About Genmab A/SGenmab is a publicly traded, international biotechnology company specializingin the creation and development of differentiated human antibody therapeuticsfor the treatment of cancer. Founded in 1999, the company's first marketedantibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocyticleukemia in patients who are refractory to fludarabine and alemtuzumab afterless than eight years in development. Genmab's validated and next generationantibody technologies are expected to provide a steady stream of future productcandidates. Partnering of innovative product candidates and technologies is akey focus of Genmab's strategy and the company has alliances with top tierpharmaceutical and biotechnology companies. For more information visitwww.genmab.com.Contact:Rachel Curtis Gravesen, Senior Vice President, Investor Relations &CommunicationsT: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.comThis Company Announcement contains forward looking statements. The words'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressionsidentify forward looking statements. Actual results or performance may differmaterially from any future results or performance expressed or implied by suchstatements. The important factors that could cause our actual results orperformance to differ materially include, among others, risks associated withpre-clinical and clinical development of products, uncertainties related to theoutcome and conduct of clinical trials including unforeseen safety issues,uncertainties related to product manufacturing, the lack of market acceptanceof our products, our inability to manage growth, the competitive environment inrelation to our business area and markets, our inability to attract and retainsuitably qualified personnel, the unenforceability or lack of protection of ourpatents and proprietary rights, our relationships with affiliated entities,changes and developments in technology which may render our products obsolete,and other factors. For a further discussion of these risks, please refer to therisk management sections in Genmab's most recent financial reports, which areavailable on www.genmab.com. Genmab does not undertake any obligation to updateor revise forward looking statements in this Company Announcement nor toconfirm such statements in relation to actual results, unless required by law.Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); HuMax(r)-EGFr;HuMax(r)-IL8; HuMax(r)-TAC; HuMax(r)-CD38; HuMax(r)-TF; HuMax(r)-TF-ADC; HuMax(r)-Her2;HuMax(r)-cMet, HuMax(r)-CD74, DuoBody(tm) and UniBody(r) are all trademarks of GenmabA/S. Arzerra(r) is a trademark of GlaxoSmithKline.Company Announcement no. 17CVR no. 2102 3884Genmab A/SBredgade 341260 Copenhagen KDenmarkClick on, or paste the following link into your web browser, to view the associated documentshttps://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=398325News Source: NASDAQ OMX12.07.2012 DGAP's Distribution Services include Regulatory Announcements,Financial/Corporate News and Press Releases.Media archive at www.dgap-medientreff.de and www.dgap.de---------------------------------------------------------------------------Language: EnglishCompany: Genmab A/S DenmarkPhone:Fax:E-mail:Internet:ISIN: DK0010272202WKN:End of Announcement DGAP News-Service---------------------------------------------------------------------------